インフルエンザワクチンの世界市場レポート 2025年

インフルエンザワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年には110億2,000万米ドルに成長し、CAGRは8.7%となります。予測期間における成長の要因としては、気候や環境要因、ヘルスケアへのアクセスの改善、新型インフルエンザの出現、アジュバントやデリバリーシステムの革新、医療費の増加などが挙げられます。予測期間における主な動向としては、MRNAワクチン技術の利用拡大、小児予防接種の重点化、季節性インフルエンザ対策、発展途上国におけるワクチン接種率の向上、個別接種戦略などが挙げられます。

季節性インフルエンザの罹患率の増加が、今後のインフルエンザワクチン市場の成長を牽引すると予想されます。季節性インフルエンザは、インフルエンザウイルスによって引き起こされる呼吸器疾患であり、通常、1年の特定の時期（通常は寒い時期）に流行します。このような動向は、抗原のドリフト、集団の感受性、環境の影響、ワクチン接種の不完全さ、普遍的なワクチン接種の不在などの要因によって生じています。インフルエンザワクチンは、季節性インフルエンザの発生を減少させるために、循環しているウイルス株に対する予防接種を行うという重要な役割を担っています。例えば、2023年11月、米国を拠点とする政府機関である疾病対策予防センター（CDC）は、2022-2023年のインフルエンザシーズンにおいて、インフルエンザに関連する罹患者数は約3,100万人、インフルエンザに関連する受診者数は1,400万人、インフルエンザに関連する入院者数は36万人、インフルエンザに関連する死亡者数は2万1,000人であったと報告しました。このように、季節性インフルエンザの罹患率の上昇が、インフルエンザワクチン市場の成長を促進しています。

インフルエンザワクチン市場の成長は、高齢化人口の増加によってさらに促進されると予想されます。この人口動向は、社会における高齢者の割合の増加を意味し、この人口層は、インフルエンザ感染に伴う重篤な合併症や死亡率に対する感受性の高まりを緩和するためにインフルエンザワクチンを利用しています。加齢によって免疫力が低下すると、インフルエンザなどの感染症にかかりやすくなります。2022年10月の世界保健機関（WHO）によると、60歳以上の世界人口は2050年までに倍増し、21億人に達すると予測されています。したがって、高齢化社会の拡大はインフルエンザワクチン市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界インフルエンザワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のインフルエンザワクチン市場：成長率分析
• 世界のインフルエンザワクチン市場の実績：規模と成長, 2019-2024
• 世界のインフルエンザワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界インフルエンザワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインフルエンザワクチン市場ワクチンの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活性化
• 生弱毒化
• 世界のインフルエンザワクチン市場ヴァレンシー、実績と予測, 2019-2024, 2024-2029F, 2034F
• 四価
• 三価
• 世界のインフルエンザワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射
• 鼻スプレー
• 世界のインフルエンザワクチン市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 成人用
• 世界のインフルエンザワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と薬局
• 政府および機関による供給
• その他の流通チャネル
• 世界のインフルエンザワクチン市場、不活性化のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 三価不活化ワクチン（TIV）
• 四価不活化ワクチン（QIV）
• 世界のインフルエンザワクチン市場、タイプ別の弱毒生菌のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ライブ減衰インフルエンザワクチン（LAIV）
• 四価生弱毒化インフルエンザワクチン（QLAIV）

第7章 地域別・国別分析

• 世界のインフルエンザワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のインフルエンザワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インフルエンザワクチン市場：競合情勢
• インフルエンザワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi-Aventis LLC. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• GlaxoSmithKline plc.
• Serum Institute of India Private Limited
• Takeda Pharmaceutical Company Limited
• Moderna Inc.
• Viatris Inc.
• CSL Limited
• Seqirus Inc.
• Daiichi Sankyo Company Limited
• China National Pharmaceutical Group Corporation
• Shanghai Fosun Pharmaceutical Group Co. Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Shionogi & Co. Ltd.
• Liaoning Cheng Da Biotechnology Co. Ltd.
• Novavax AB

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インフルエンザワクチン市場2029：新たな機会を提供する国
• インフルエンザワクチン市場2029：新たな機会を提供するセグメント
• インフルエンザワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Influenza vaccines, commonly known as flu vaccines, are designed to confer immunity against influenza viruses. These vaccines are quadrivalent, meaning they are formulated to provide protection against four different flu viruses, encompassing two influenza A viruses and two influenza B viruses.

The primary types of influenza vaccines are inactivated and live attenuated vaccines. Inactivated vaccines contain killed or inactivated microorganisms or viruses, stimulating an immune response without causing the disease. They are used to prevent infection and reduce the severity of illness caused by influenza viruses. Inactivated vaccines are available in both quadrivalent and trivalent formulations and are administered through injections and nasal sprays. These vaccines are suitable for both pediatric and adult populations and are distributed through various channels, including hospitals and pharmacies, government and institutional supply, and other distribution networks.

The influenza vaccines market research report is one of a series of new reports from The Business Research Company that provides influenza vaccines market statistics, including influenza vaccines industry global market size, regional shares, competitors with an influenza vaccines market share, detailed influenza vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. This influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza vaccines market size has grown strongly in recent years. It will grow from $7.35 billion in 2024 to $7.9 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to pandemic preparedness, public health initiatives, vaccine effectiveness studies, healthcare professional recommendations, global influenza surveillance

The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $11.02 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to climate and environmental factors, healthcare accessibility improvement, emergence of new influenza strains, innovation in adjuvants and delivery systems, rising healthcare expenditure. Major trends in the forecast period include wider use of mrna vaccine technology, pediatric immunization focus, seasonal influenza control measures, enhanced vaccination coverage in developing nations, tailored vaccination strategies.

The increasing incidence of seasonal influenza is expected to drive growth in the influenza vaccine market in the future. Seasonal influenza is a respiratory illness caused by influenza viruses that typically circulate during specific times of the year, usually in the colder months. This trend has emerged due to factors such as antigenic drift, population susceptibility, environmental influences, incomplete vaccine coverage, and the absence of universal vaccination. Influenza vaccines play a crucial role in reducing the incidence of seasonal influenza by providing immunization against the circulating strains of the virus. For instance, in November 2023, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that during the 2022-2023 flu season, there were approximately 31 million flu-related illnesses, 14 million flu-related medical visits, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Thus, the rising incidence of seasonal influenza is propelling the growth of the influenza vaccine market.

The growth of the influenza vaccines market is further expected to be propelled by the increasing aging population. This demographic trend refers to a rising proportion of elderly individuals within a society, and this population segment utilizes influenza vaccines to mitigate the heightened susceptibility to severe complications and mortality associated with influenza infections. The aging process may lead to a weakening immune system, rendering individuals more vulnerable to infectious diseases such as influenza. According to the World Health Organization (WHO) in October 2022, the global population of people aged 60 years and older is projected to double by 2050, reaching 2.1 billion. Therefore, the expanding aging population is a significant driver of the influenza vaccines market.

An emerging trend in the influenza vaccine market is the adoption of technologically advanced vaccine production methods. Companies operating in this market are embracing innovative vaccine production technologies to maintain their competitive positions. For example, in January 2023, GlaxoSmithKline PLC introduced the Multiple Antigen Presenting System (MAPS) for vaccine development, offering an innovative approach to developing effective vaccines against bacteria and viruses. This technology is particularly useful for rapid vaccine development in response to epidemic or pandemic outbreaks.

Major companies in the influenza vaccine market are focusing on advanced product innovations, such as quadrivalent seasonal influenza vaccines, to enhance their respiratory vaccine portfolios and financial standings. A quadrivalent seasonal influenza vaccine is designed to provide protection against four different flu viruses, including two influenza A viruses and two influenza B viruses. In September 2023, Clover Biopharmaceuticals Ltd. launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent composition enhances the vaccine's effectiveness across different influenza B strains compared to trivalent options.

In November 2022, Pfizer Inc. entered into a partnership with BioNTech SE to develop an mRNA combination vaccine for influenza and COVID-19. This collaboration aims to initiate a phase I trial for a single-dose mRNA-based combination addressing both respiratory diseases. BioNTech SE, a Germany-based immunotherapy developer, is partnering with Pfizer Inc., a US-based pharmaceutical and biotechnology company, to advance this innovative approach to respiratory disease prevention.

Major companies operating in the influenza vaccines market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.

North America was the largest region in the influenza vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the influenza vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Influenza Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on influenza vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for influenza vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The influenza vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Inactivated; Live Attenuated
• 2) By Valency: Quadrivalent; Trivalent
• 3) By Route Of Administration: Injection; Nasal Spray
• 4) By Age Group: Pediatric; Adult
• 5) By Distribution Channel: Hospitals And Pharmacies; Government And Institutional Supply; Other Distribution Channels
• Subsegments:
• 1) By Inactivated: Trivalent Inactivated Vaccines (TIV); Quadrivalent Inactivated Vaccines (QIV)
• 2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV); Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi-Aventis LLC.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Influenza Vaccines Market Characteristics

3. Influenza Vaccines Market Trends And Strategies

4. Influenza Vaccines Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Influenza Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Influenza Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Influenza Vaccines Market Growth Rate Analysis
• 5.4. Global Influenza Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Influenza Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Influenza Vaccines Total Addressable Market (TAM)

6. Influenza Vaccines Market Segmentation

• 6.1. Global Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated
• Live Attenuated
• 6.2. Global Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Quadrivalent
• Trivalent
• 6.3. Global Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection
• Nasal Spray
• 6.4. Global Influenza Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• 6.5. Global Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals and Pharmacies
• Government and Institutional Supply
• Other Distribution Channels
• 6.6. Global Influenza Vaccines Market, Sub-Segmentation Of Inactivated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trivalent Inactivated Vaccines (TIV)
• Quadrivalent Inactivated Vaccines (QIV)
• 6.7. Global Influenza Vaccines Market, Sub-Segmentation Of Live Attenuated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Influenza Vaccines (LAIV)
• Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

7. Influenza Vaccines Market Regional And Country Analysis

• 7.1. Global Influenza Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Influenza Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Influenza Vaccines Market

• 8.1. Asia-Pacific Influenza Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Influenza Vaccines Market

• 9.1. China Influenza Vaccines Market Overview
• 9.2. China Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Influenza Vaccines Market

• 10.1. India Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Influenza Vaccines Market

• 11.1. Japan Influenza Vaccines Market Overview
• 11.2. Japan Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Influenza Vaccines Market

• 12.1. Australia Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Influenza Vaccines Market

• 13.1. Indonesia Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Influenza Vaccines Market

• 14.1. South Korea Influenza Vaccines Market Overview
• 14.2. South Korea Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Influenza Vaccines Market

• 15.1. Western Europe Influenza Vaccines Market Overview
• 15.2. Western Europe Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Influenza Vaccines Market

• 16.1. UK Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Influenza Vaccines Market

• 17.1. Germany Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Influenza Vaccines Market

• 18.1. France Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Influenza Vaccines Market

• 19.1. Italy Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Influenza Vaccines Market

• 20.1. Spain Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Influenza Vaccines Market

• 21.1. Eastern Europe Influenza Vaccines Market Overview
• 21.2. Eastern Europe Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Influenza Vaccines Market

• 22.1. Russia Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Influenza Vaccines Market

• 23.1. North America Influenza Vaccines Market Overview
• 23.2. North America Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Influenza Vaccines Market

• 24.1. USA Influenza Vaccines Market Overview
• 24.2. USA Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Influenza Vaccines Market

• 25.1. Canada Influenza Vaccines Market Overview
• 25.2. Canada Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Influenza Vaccines Market

• 26.1. South America Influenza Vaccines Market Overview
• 26.2. South America Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Influenza Vaccines Market

• 27.1. Brazil Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Influenza Vaccines Market

• 28.1. Middle East Influenza Vaccines Market Overview
• 28.2. Middle East Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Influenza Vaccines Market

• 29.1. Africa Influenza Vaccines Market Overview
• 29.2. Africa Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Influenza Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Influenza Vaccines Market Competitive Landscape
• 30.2. Influenza Vaccines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi-Aventis LLC. Overview, Products and Services, Strategy and Financial Analysis

31. Influenza Vaccines Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline plc.
• 31.3. Serum Institute of India Private Limited
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Moderna Inc.
• 31.6. Viatris Inc.
• 31.7. CSL Limited
• 31.8. Seqirus Inc.
• 31.9. Daiichi Sankyo Company Limited
• 31.10. China National Pharmaceutical Group Corporation
• 31.11. Shanghai Fosun Pharmaceutical Group Co. Ltd.
• 31.12. Mitsubishi Tanabe Pharma Corporation
• 31.13. Shionogi & Co. Ltd.
• 31.14. Liaoning Cheng Da Biotechnology Co. Ltd.
• 31.15. Novavax AB

32. Global Influenza Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Influenza Vaccines Market

34. Recent Developments In The Influenza Vaccines Market

35. Influenza Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Influenza Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Influenza Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Influenza Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer